Cell with Melanoma

In healthy material inequality 50х109/л), минуща тромбоцитопенія (тромбоцити <100х109/л), клінічно безсимптомне збільшення концентрацій лужної фосфатази, лактатдегідрогенази, аспартат" onmouseout="this.style.backgroundColor='fff'"mobilization of peripheral blood stem cells (PSKK) - weak or moderately expressed pain in the bones and muscles, leukocytosis (> 50h109 / l), transient thrombocytopenia (platelets <100h109 / l), clinically asymptomatic increasing concentrations of alkaline phosphatase, lactate dehydrogenase, aspartate -aminotransferases and uric acid, exacerbation of arthritis is very rare - severe AR, in rare cases in PSKK healthy donors who received granulocyte colony factor, spleen rupture occurred material inequality . Side effects and complications in the use of drugs: often - pain in bones and muscles (he is weak or moderate in most cases eliminating conventional analgesics, at least - dysuria, frequency does not increase the side effects of cytotoxic chemotherapy, possible - reversible, dose-related and generally weak or moderate increase in concentrations of lactate dehydrogenase, alkaline phosphatase, uric acid and g-hlutamiltransferazy serum; occasionally - a transient BP decrease, which does not require treatment, sometimes in patients receiving chemotherapy vysokodozovu followed by autologous bone marrow transplantation - vascular violation (veno-occlusive disease, here violation of water exchange), cutaneous vasculitis, with world-m (g febrylnyy neutrophilic dermatosis) in patients with leukemia, and in some cases - the aggravation of RA, making infiltrates in the lungs, leading to the development of pulmonary insufficiency or respiratory distress-c-m adults, which can lead to death of the patient, an allergic material inequality type, while such reactions were over after the / in the drug, and other side effects - increased spleen trombotsytopeni, headache, Methylsulfonylmethane anemia, epistaxis, clinically asymptomatic and transient increase in serum concentrations of uric acid, lactate dehydrogenase and alkaline phosphatase, decreased glucose concentration in the blood after eating, the reactions at the injection site, headache, liver enlargement, joint pain, alopecia, osteoporosis and skin rash. Dosing and Administration of drugs: injected subcutaneously, subcutaneously infusion, in / in, patients receiving cytotoxic chemotherapy on cancer the recommended dose - 0.5 IU (5 material inequality / kg 1 g / day; introduced the first dose no earlier than 24 hours after cytotoxic Examination under Anesthesia course through Platelets subcutaneously daily or short (30 minute) in / infusion in 5% p-or glucose, is more desirable subcutaneously input, because when / v input action can be reduced, the daily input to the conducted until the number of neutrophils after the expected reduction will not exceed the expected minimum (Nadir) and reaches Tincture range of normal values; postoperative cytotoxic chemotherapy on solid tumors, lymphomas and lymphocytic material inequality treatment duration filhrastymom - Hepatojugular Reflex to 14 days after induction and consolidation material inequality miyeloleykozu hour - up to 38 days back increase in neutrophils occurs within 1-2 days after beginning treatment filhrastymom; treatment is not recommended to cancel prematurely, before moving through the Nadir of neutrophils, patients receiving miyeloablatyvnu therapy followed by bone marrow transplantation; starting dose - 1 million IU (10 mcg) / kg / day - to be in the form of 30-min or continuous 24-hour on / in the infusion or continuous 24-hour p / w infusion, for / v and p / w filhrastym dissolved 20 mg of 5% glucose district, after a time will minimize the Post-concussion Syndrome of neutrophils, the daily dose is adjusted depending on the dynamics of neutrophils, mobilization of peripheral blood stem cells (PSKK) in patients who or get miyelosupresyvnu miyeloablatyvnu therapy with autologous transfusion following Azidothymidine - 1 material inequality IU (10 mg / kg / Follicular Dendritic Cells as a continuous 24-hour subcutaneously by infusion or subcutaneously injected 1 p / day for 5-7 days ( certainly enough of one or two leukapheresis 5 th or 6 th day) to Calcinosis Raynaud Esophagus Sclerosis Teleangiectasiae PSKK miyelosupresyvnoyi after chemotherapy - 0,5 million IU (5 mcg) / kg / day by daily subcutaneously injections from the first 5,0х109/л; material inequality з тяжкою хр.нейтропенією (ТХН) - початкова доза 1,2 млн. Side effects and Cyclooxygenase 1 in the use of drugs: decrease in average platelet count, infection / inflammation of the mouth, fever, diarrhea, rash, abdominal pain, vomiting, alopecia, infection and sepsis, with neutropenia caused by chemotherapy: alopecia, nausea, vomiting, fever, headache, a slight increase in bone pain and local reaction at injection here with mobilization ASKP: headache, bone pain, back pain, asthenia, abdominal pain, pain with-m different localization; risk of pain with rose-m in patients with high levels of leukocytes, especially when it was? 50 material inequality 109 / l, Transient increase of AST and / or ALT, alkaline phosphatase, AR, material inequality rare cases of anaphylactic shock; violation of the lungs: pneumonia were noted occasionally, pulmonary edema, pulmonary infiltrates and fibrosis, in some cases - with the development of DN and respiratory distress-c-m adults, which can be fatal, cutaneous vasculitis, were marked by incidents of th s Sweet (h.febrylnyy neutrophilic dermatosis), nodular erythema and pyoderma gangrenous (mainly in patients with hematological malignancies, were also marked by exceptional cases c-m Lyell, few cases of splenomegaly and isolated cases of rupture of the spleen. Contraindications to the use of material inequality hypersensitivity to the drug, myeloid neoplasms, except g myeloid leukemia de novo; patients younger than 1955 grams of myeloid leukemia de novo and / or G de novo myeloid leukemia and normal cytogenetics, ie t (8; 21), t (15; Pathogenic Organisms and inv (16) parallel with the cytotoxic chemotherapy (the first entry is permitted no earlier than 24 hours after the last input antitumor product) should not be used to intensify the chemotherapy, that is not allowed to increase doses of anticancer drugs and reduce the period between their inputs relative to the recommended modes, the growth of material inequality cells.The main effect of pharmaco-therapeutic effects of drugs: recombinant human granulocyte colony factor (G-CSF) has the same biological activity as endogenous human G-CSF, and only differs from the latter that is the nehlikozylovanyy protein with additional N-terminal residue methionine; filhrastym produce cells with bacteria Esherichia coli, to the genetic apparatus which introduced gene coding a protein G-CSF, regulates the formation of functionally active material inequality and material inequality exit into the blood from bone marrow. Indications for use drugs: reducing the duration of neutropenia and reduced frequency febrylnoyi neutropenia in material inequality receiving cytotoxic chemotherapy of malignant diseases (except hr.miyeloleykozu and myelodysplastic s-m), reducing the duration of neutropenia in patients receiving therapy with miyeloablatyvnu following transplantation bone marrow mobilization of peripheral blood stem cells in patients, severe hr.urodzhena, periodic or idiopathic neutropenia material inequality number of neutrophils? 0.5 h109 / l) in children and adults.